Vyne Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $69 | $202 | $84 | $121 |
Gross Profit | 69 | 202 | 84 | 121 |
EBITDA | -7,536 | -9,191 | -12,770 | -13,091 |
EBIT | -7,542 | -9,197 | -12,774 | |
Net Income | -5,755 | -8,611 | -12,022 | -12,157 |
Net Change In Cash | 69 | 202 | 84 | 121 |
Free Cash Flow | -10,803 | -11,461 | -9,116 | -8,510 |
Cash | 22,047 | 28,209 | 19,926 | 16,272 |
Basic Shares | 42,759 | 42,673 | 42,588 | 42,587 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $501 | $424 | $477 | $14,755 |
Gross Profit | 501 | 424 | 477 | 11,407 |
EBITDA | -43,633 | -29,258 | -34,223 | -38,937 |
EBIT | -43,637 | -29,003 | -34,295 | -39,046 |
Net Income | -39,834 | -28,452 | -33,945 | -73,329 |
Net Change In Cash | 501 | 424 | 477 | 14,755 |
Free Cash Flow | -34,089 | -25,341 | -29,200 | -56,367 |
Cash | 19,926 | 30,620 | 30,908 | 42,250 |
Basic Shares | 42,589 | 10,273 | 3,185 | 2,858 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.13 |
2025-03-31 | -$0.20 |
2024-12-31 | -$0.28 |
2024-09-30 | -$0.29 |
